A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma

Trial Profile

A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Poly ICLC (Primary) ; Temozolomide
  • Indications Astrocytoma; Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Jul 2017 Planned End Date changed from 30 Jun 2019 to 31 Oct 2019.
    • 18 Jul 2017 Planned primary completion date changed from 31 Aug 2017 to 31 Dec 2017.
    • 16 Feb 2017 Phase has been changed from phase 0 to phase 1.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top